IL304924A - Methods for ophthalmic delivery of roflumilast - Google Patents
Methods for ophthalmic delivery of roflumilastInfo
- Publication number
- IL304924A IL304924A IL304924A IL30492423A IL304924A IL 304924 A IL304924 A IL 304924A IL 304924 A IL304924 A IL 304924A IL 30492423 A IL30492423 A IL 30492423A IL 304924 A IL304924 A IL 304924A
- Authority
- IL
- Israel
- Prior art keywords
- roflumilast
- eye
- pharmaceutical composition
- concentration
- cornea
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 33
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims description 181
- 229960002586 roflumilast Drugs 0.000 claims description 179
- 239000008194 pharmaceutical composition Substances 0.000 claims description 77
- 210000004087 cornea Anatomy 0.000 claims description 66
- 210000001519 tissue Anatomy 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 39
- 210000003786 sclera Anatomy 0.000 claims description 31
- 210000001742 aqueous humor Anatomy 0.000 claims description 26
- 210000000795 conjunctiva Anatomy 0.000 claims description 25
- 239000000725 suspension Substances 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 10
- 210000001508 eye Anatomy 0.000 description 99
- 239000003814 drug Substances 0.000 description 57
- 229940079593 drug Drugs 0.000 description 50
- 210000000695 crystalline len Anatomy 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 238000009472 formulation Methods 0.000 description 19
- PCGSQNPMMSALEJ-UHFFFAOYSA-N roflumilast n-oxide Chemical compound ClC1=C[N+]([O-])=CC(Cl)=C1NC(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 PCGSQNPMMSALEJ-UHFFFAOYSA-N 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 238000009826 distribution Methods 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 9
- 239000002674 ointment Substances 0.000 description 9
- 239000007979 citrate buffer Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000004127 vitreous body Anatomy 0.000 description 7
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 6
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 210000000871 endothelium corneal Anatomy 0.000 description 6
- 208000030533 eye disease Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000003560 epithelium corneal Anatomy 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000007971 pharmaceutical suspension Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000022873 Ocular disease Diseases 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 4
- 208000002205 allergic conjunctivitis Diseases 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 210000003683 corneal stroma Anatomy 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 229940100654 ophthalmic suspension Drugs 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229940066842 petrolatum Drugs 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 description 3
- 208000010217 blepharitis Diseases 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 235000003484 annual ragweed Nutrition 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000006263 bur ragweed Nutrition 0.000 description 2
- 229940057850 carbomer copolymer type a Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 235000003488 common ragweed Nutrition 0.000 description 2
- -1 cyclopropylmethoxy Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 235000009736 ragweed Nutrition 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 229960004224 tyloxapol Drugs 0.000 description 2
- 229920001664 tyloxapol Polymers 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical class CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010057380 Allergic keratitis Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 206010072138 Limbal stem cell deficiency Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010072139 Ocular rosacea Diseases 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 206010062889 Pingueculitis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001621636 Pterygia Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940006829 daliresp Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 201000001757 phlyctenulosis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012027 sterile manufacturing Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000025889 stromal keratitis Diseases 0.000 description 1
- 208000024205 superior limbic keratoconjunctivitis Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148008P | 2021-02-10 | 2021-02-10 | |
| US202163261404P | 2021-09-20 | 2021-09-20 | |
| PCT/US2022/015942 WO2022173923A1 (en) | 2021-02-10 | 2022-02-10 | Methods for ophthalmic delivery of roflumilast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304924A true IL304924A (en) | 2023-10-01 |
Family
ID=82704332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304924A IL304924A (en) | 2021-02-10 | 2022-02-10 | Methods for ophthalmic delivery of roflumilast |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12102622B2 (https=) |
| EP (1) | EP4291162A4 (https=) |
| JP (1) | JP2024506384A (https=) |
| AU (1) | AU2022218993A1 (https=) |
| CA (1) | CA3206106A1 (https=) |
| IL (1) | IL304924A (https=) |
| MX (1) | MX2023009352A (https=) |
| WO (1) | WO2022173923A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023049809A1 (en) * | 2021-09-22 | 2023-03-30 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| AU2023341161A1 (en) * | 2022-09-16 | 2025-04-03 | Iolyx Therapeutics, Inc. | High concentration pharmaceutical compositions of roflumilast for ophthalmic delivery |
| WO2025024684A1 (en) * | 2023-07-25 | 2025-01-30 | Iolyx Therapeutics, Inc. | Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59410119D1 (de) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| SK122199A3 (en) | 1997-03-18 | 2000-12-11 | Basf Ag | Methods and compositions for modulating responsiveness to corticosteroids |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| US20040242597A1 (en) | 2001-09-19 | 2004-12-02 | Thomas Klein | Combination |
| PT1511516E (pt) | 2002-05-28 | 2009-02-20 | Nycomed Gmbh | Preparação farmacêutica para aplicação tópica |
| US20060263350A1 (en) | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| AU2005267706B2 (en) | 2004-08-02 | 2011-12-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
| US7576069B2 (en) | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| US8663694B2 (en) * | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
| DK1906916T3 (da) * | 2005-05-10 | 2009-01-19 | Alcon Inc | Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser |
| BRPI0609227A2 (pt) | 2005-05-10 | 2010-03-09 | Alcon Inc | composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos |
| EP1889620A4 (en) * | 2005-06-09 | 2008-12-10 | Santen Pharmaceutical Co Ltd | EYE DROPS CONTAINING ROFLUMILAST |
| JP2007016024A (ja) * | 2005-06-09 | 2007-01-25 | Santen Pharmaceut Co Ltd | ロフルミラスト点眼液 |
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| CA2712017C (en) | 2008-01-18 | 2016-08-09 | Oxagen Limited | Compounds having crth2 antagonist activity |
| RS54413B1 (sr) | 2008-08-22 | 2016-04-28 | Sanofi | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita |
| EP2506878A2 (en) | 2009-12-03 | 2012-10-10 | Lupin Limited | Process for preparing pharmaceutical ophthalmic compositions |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| WO2015132708A1 (en) | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| TW201729810A (zh) | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| MX2021003633A (es) | 2018-10-16 | 2021-05-27 | Res Triangle Inst | Dispositivo de depósito biodegradable subcutáneo. |
| EP4061332A4 (en) | 2019-11-24 | 2023-11-29 | Sol-Gel Technologies Ltd. | TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR |
| WO2023049809A1 (en) * | 2021-09-22 | 2023-03-30 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
-
2022
- 2022-02-10 US US17/668,858 patent/US12102622B2/en active Active
- 2022-02-10 MX MX2023009352A patent/MX2023009352A/es unknown
- 2022-02-10 JP JP2023548873A patent/JP2024506384A/ja active Pending
- 2022-02-10 IL IL304924A patent/IL304924A/en unknown
- 2022-02-10 EP EP22753325.4A patent/EP4291162A4/en active Pending
- 2022-02-10 WO PCT/US2022/015942 patent/WO2022173923A1/en not_active Ceased
- 2022-02-10 AU AU2022218993A patent/AU2022218993A1/en active Pending
- 2022-02-10 CA CA3206106A patent/CA3206106A1/en active Pending
-
2024
- 2024-09-26 US US18/897,425 patent/US20250009724A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023009352A (es) | 2023-08-16 |
| WO2022173923A1 (en) | 2022-08-18 |
| US20250009724A1 (en) | 2025-01-09 |
| AU2022218993A1 (en) | 2023-08-03 |
| US20220249451A1 (en) | 2022-08-11 |
| CA3206106A1 (en) | 2022-08-18 |
| US12102622B2 (en) | 2024-10-01 |
| EP4291162A1 (en) | 2023-12-20 |
| JP2024506384A (ja) | 2024-02-13 |
| EP4291162A4 (en) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304924A (en) | Methods for ophthalmic delivery of roflumilast | |
| IL276918B2 (en) | Ophthalmic formulation comprising albumin and an active compound | |
| JP7018939B2 (ja) | 眼疾患の治療のための組成物ならびに使用および調製方法 | |
| JP2020530470A (ja) | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 | |
| US20250195489A1 (en) | Methods of treating ocular inflammatory diseases | |
| US10010586B2 (en) | Method of treating intraocular tissue pathologies with nerve growth factor | |
| KR102578102B1 (ko) | 엔도텔린 수용체 길항제의 국소 안용 제형 | |
| Vickers et al. | The future of dry eye treatment: a glance into the therapeutic pipeline | |
| IL251769B (en) | Varnicline compound for use as a drug for treating dry eye, increasing tear production and treating eye discomfort and a premebacte preparation containing Varnicline | |
| US20160051526A1 (en) | The Local Treatment of Inflammatory Ophthalmic Disorders | |
| CN116867480A (zh) | 眼部递送罗氟司特的方法 | |
| IL274810B2 (en) | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface | |
| Cagini et al. | Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application | |
| IL302062A (en) | Preservative-free ophthalmic pharmaceutical emulsion and its application | |
| Singh et al. | Formulation and evaluation of in-situ gelling system for sustained release ophthalmic drug delivery of ciprofloxacin | |
| HK40101566A (zh) | 眼部递送罗氟司特的方法 | |
| IL300724A (en) | Methods of neuroprotection and its uses | |
| Bisen et al. | Corneal Targeted Mucoadhesive Emulsion for Prolonged Delivery of Voriconazole: Formulation Evaluation and Pharmacokinetic Assessment | |
| Willms et al. | Minocycline and diacetyl minocycline eye drops reduce ocular neovascularization in mice | |
| US20250032468A1 (en) | Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases | |
| CN107921053B (zh) | 用于治疗或预防干眼症的方法 | |
| Tatke | Development and Evaluation of Topical Formulation Designs for Improved Drug Delivery to the Posterior Ocular Tissues | |
| Patel | Development and Evaluation of a Nanomicellar Eye Drop Formulation of Dexamethasone for Posterior Uveitis | |
| Chand et al. | OCULAR DRUG DELIVERY: AN APPROACH TO CURRENT MEDICATION | |
| US20140213605A1 (en) | Methods for treating eye disorders using opioid receptor antagonists |